Recent Updates
Recently added Catalysts

CP-675, 206 and leuprolide and bicalutamide

Phase 1

Prostatic Neoplasms | Small molecule | Oncology |AstraZeneca PLC|Last Updated: Jun 6, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment8

FDA Designations

No designations recorded

Clinical trial landscape

CP-675, 206 and leuprolide and bicalutamide · 1 trial · 1 indication

Phase 1 1
NCT00075192CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate CancerProstatic Neoplasms
COMPLETED8 Analytics
PHASE1COMPLETED
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
Prostatic Neoplasms
NCT000751928
Unlock trial analytics

Study Endpoints

Primary Endpoints

Assess safety of combination therapy and effectiveness as assessed by pathological response after 3 months of treatment follow for disease status for a maximum of 24 months

Secondary Endpoints

assess Pk during treatment monitor for human anti-human antibodies at the end of the study explore genetic influences on safety and/or immune response
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
CP-675,206 and leuprolide acetate and bicalutamideDRUG -
leuprolide acetate and bicalutamideDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate, previously untreated * Potential candidate for radical prostatectomy on the basis of the patient's general medical condition, performance status, and life expectancy * Potential candidate for NHT prior to prostatectomy, ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about CP-675, 206 and leuprolide and bicalutamide

What is CP-675,206 used for?

CP-675,206 is an investigational oncology therapy being studied in prostatic neoplasms, melanoma, pancreatic cancer, renal cell carcinoma, non-small-cell lung cancer, and colorectal neoplasms. It is a small molecule being developed by AstraZeneca PLC and is currently in Phase 2 clinical development.

What does CP-675,206 target?

CP-675,206 is a small molecule oncology therapy. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being investigated across multiple solid tumor types including melanoma, renal cell carcinoma, and non-small-cell lung cancer.

Who makes CP-675,206?

CP-675,206 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 2 clinical trials for multiple oncology indications.

What phase is CP-675,206 in?

CP-675,206 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, along with two Phase 1 trials, with a total enrollment of 740 patients across all studies.

What clinical trials is CP-675,206 in?

CP-675,206 has completed two Phase 2 trials: NCT00086489 in advanced melanoma and NCT00312975 in non-small-cell lung cancer. Two Phase 1 trials, NCT00372853 in metastatic renal cell carcinoma and NCT00431275 in melanoma, have also been completed. All trials are closed.

Is CP-675,206 the same as tremelimumab?

CP-675,206 is an investigational monoclonal antibody being developed by AstraZeneca. While it has been studied in oncology indications, no alternative names have been established in the clinical trial records. The drug remains in Phase 2 development.